JP2011506476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506476A5 JP2011506476A5 JP2010538191A JP2010538191A JP2011506476A5 JP 2011506476 A5 JP2011506476 A5 JP 2011506476A5 JP 2010538191 A JP2010538191 A JP 2010538191A JP 2010538191 A JP2010538191 A JP 2010538191A JP 2011506476 A5 JP2011506476 A5 JP 2011506476A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- sialic acid
- terminal sialic
- composition
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 125000005629 sialic acid group Chemical group 0.000 claims 23
- 102000003886 Glycoproteins Human genes 0.000 claims 16
- 108090000288 Glycoproteins Proteins 0.000 claims 16
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 150000004676 glycans Polymers 0.000 claims 12
- 150000004804 polysaccharides Polymers 0.000 claims 12
- 108090001090 Lectins Proteins 0.000 claims 6
- 102000004856 Lectins Human genes 0.000 claims 6
- 239000002523 lectin Substances 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 238000001042 affinity chromatography Methods 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 230000009450 sialylation Effects 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- UQBIAGWOJDEOMN-UHFFFAOYSA-N 2-O-(2-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranosyl)-D-mannopyranose Natural products OC1C(O)C(CO)OC(O)C1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 UQBIAGWOJDEOMN-UHFFFAOYSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 1
- 108010021470 Fc gamma receptor IIC Proteins 0.000 claims 1
- 108010001496 Galectin 2 Proteins 0.000 claims 1
- 102100021735 Galectin-2 Human genes 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/957,015 US20080206246A1 (en) | 2006-04-05 | 2007-12-14 | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| PCT/US2008/086622 WO2009079382A1 (en) | 2007-12-14 | 2008-12-12 | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506476A JP2011506476A (ja) | 2011-03-03 |
| JP2011506476A5 true JP2011506476A5 (enExample) | 2012-02-02 |
Family
ID=40796321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538191A Withdrawn JP2011506476A (ja) | 2007-12-14 | 2008-12-12 | 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080206246A1 (enExample) |
| EP (1) | EP2227255A4 (enExample) |
| JP (1) | JP2011506476A (enExample) |
| CN (1) | CN101896202A (enExample) |
| AU (1) | AU2008338550A1 (enExample) |
| CA (1) | CA2707304A1 (enExample) |
| EA (1) | EA201070739A1 (enExample) |
| IL (1) | IL206029A0 (enExample) |
| MX (1) | MX2010006537A (enExample) |
| WO (1) | WO2009079382A1 (enExample) |
| ZA (1) | ZA201004045B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| EP3456351A1 (en) * | 2006-04-05 | 2019-03-20 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US20110150867A1 (en) * | 2007-12-14 | 2011-06-23 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| EP2279410B1 (en) * | 2008-04-22 | 2015-11-11 | The Rockefeller University | Methods of identifying anti-inflammatory compounds |
| EP2233499A1 (en) * | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
| EP2427497B1 (fr) | 2009-05-07 | 2016-12-07 | Stallergenes | Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale |
| MX2012005527A (es) | 2009-11-13 | 2012-08-08 | Grifols Therapeutics Inc | Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas. |
| US20130058917A1 (en) * | 2010-05-07 | 2013-03-07 | Fabian Käsermann | Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column |
| WO2011149999A2 (en) * | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
| AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| CN103582650A (zh) * | 2011-05-25 | 2014-02-12 | 默沙东公司 | 用于制备具有改善性质的含Fc多肽的方法 |
| IN2014CN03072A (enExample) * | 2011-10-31 | 2015-07-31 | Merck Sharp & Dohme | |
| WO2013074598A1 (en) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
| CN104010659A (zh) | 2011-12-19 | 2014-08-27 | 洛克菲勒大学 | 非唾液酸化的抗炎多肽 |
| US12384848B2 (en) * | 2011-12-19 | 2025-08-12 | The Rockefeller University | Anti-inflammatory polypeptides |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CN110894231A (zh) | 2012-10-17 | 2020-03-20 | 康诺贝林伦瑙有限公司 | 免疫调节蛋白 |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| WO2014149067A1 (en) | 2013-03-15 | 2014-09-25 | Momenta Pharmaceuticals, Inc. | Methods related to ctla4-fc fusion proteins |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2015106123A1 (en) * | 2014-01-09 | 2015-07-16 | The Johns Hopkins University | Use of high flux scfa-derivatized monosaccharides in recombinant glycoprotein production |
| DK3221363T3 (da) | 2014-11-21 | 2020-08-10 | Bristol Myers Squibb Co | Antistoffer mod cd73 og anvendelser deraf |
| HRP20201756T8 (hr) | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| LT3303396T (lt) | 2015-05-29 | 2023-01-10 | Bristol-Myers Squibb Company | Antikūnai prieš ox40 ir jų panaudojimo būdai |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| KR20180118725A (ko) | 2016-03-04 | 2018-10-31 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| CA3016534A1 (en) | 2016-03-04 | 2017-09-08 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| IL270596B1 (en) | 2017-05-25 | 2025-09-01 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant region for use in treating cancer |
| CA3085472A1 (en) | 2017-12-19 | 2019-06-27 | The Rockefeller University | Human igg fc domain variants with improved effector function |
| KR102813744B1 (ko) | 2017-12-27 | 2025-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
| TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
| KR20210096167A (ko) | 2018-11-28 | 2021-08-04 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| KR102549282B1 (ko) * | 2019-11-18 | 2023-06-30 | 건국대학교 산학협력단 | 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물 |
| EP4114547A4 (en) * | 2020-03-05 | 2024-03-27 | Momenta Pharmaceuticals, Inc. | METHOD FOR PRODUCING HYPERSIALYLATED IMMUNOGLOBULIN |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| US20240425606A1 (en) | 2021-08-30 | 2024-12-26 | Lassen Therapeutics 1, Inc. | Anti-il-11ra antibodies |
| EP4446345A4 (en) * | 2021-12-09 | 2025-08-20 | Shanghai Bao Pharmaceuticals Co Ltd | FC POLYPEPTIDE WITH MODIFIED GLYCOSYLATION MODIFICATION |
| CN120787238A (zh) | 2023-01-06 | 2025-10-14 | 拉森医疗公司 | 用于治疗甲状腺眼病的抗IL-11Rα抗体 |
| TW202430560A (zh) | 2023-01-06 | 2024-08-01 | 美商拉森醫療公司 | 抗ｉｌ－１８ｂｐ抗體 |
| CN120530131A (zh) | 2023-01-06 | 2025-08-22 | 拉森医疗公司 | 抗il-18bp抗体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2556219B1 (fr) * | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| HUT64476A (en) * | 1990-11-23 | 1994-01-28 | Gen Hospital Corp | Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion |
| ATE289354T1 (de) * | 1999-04-15 | 2005-03-15 | Crucell Holland Bv | Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen. |
| DE19927835A1 (de) * | 1999-06-18 | 2000-12-21 | Clariant Gmbh | Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten |
| US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| US20070048740A1 (en) * | 2003-02-14 | 2007-03-01 | Research Association For Biotechnology | Full-length cDNA |
| US7155641B2 (en) * | 2003-05-15 | 2006-12-26 | Microsoft Corporation | System and method for monitoring the performance of a server |
| ME01775B (me) * | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| EP1699487A4 (en) * | 2003-12-15 | 2009-07-08 | Alexion Pharma Inc | NEW ANTI-DC-SIGN ANTIBODIES |
| AU2006283560B2 (en) * | 2005-08-19 | 2011-12-08 | Centocor, Inc. | Proteolysis resistant antibody preparations |
| CA2627981A1 (en) * | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| WO2008057634A2 (en) * | 2006-10-26 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| EP3456351A1 (en) * | 2006-04-05 | 2019-03-20 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP2009087163A (ja) * | 2007-10-01 | 2009-04-23 | Brother Ind Ltd | ジョブ実行装置及びジョブ実行方法 |
-
2007
- 2007-12-14 US US11/957,015 patent/US20080206246A1/en not_active Abandoned
-
2008
- 2008-12-12 EP EP08861005A patent/EP2227255A4/en not_active Withdrawn
- 2008-12-12 AU AU2008338550A patent/AU2008338550A1/en not_active Abandoned
- 2008-12-12 CA CA2707304A patent/CA2707304A1/en not_active Abandoned
- 2008-12-12 JP JP2010538191A patent/JP2011506476A/ja not_active Withdrawn
- 2008-12-12 CN CN2008801209089A patent/CN101896202A/zh active Pending
- 2008-12-12 WO PCT/US2008/086622 patent/WO2009079382A1/en not_active Ceased
- 2008-12-12 MX MX2010006537A patent/MX2010006537A/es not_active Application Discontinuation
- 2008-12-12 EA EA201070739A patent/EA201070739A1/ru unknown
-
2010
- 2010-05-27 IL IL206029A patent/IL206029A0/en unknown
- 2010-06-07 ZA ZA2010/04045A patent/ZA201004045B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506476A5 (enExample) | ||
| KR102489953B1 (ko) | Il-11r 결합 단백질 및 이의 용도 | |
| JP5969102B2 (ja) | 治療用イヌ免疫グロブリンおよびそれを用いる方法 | |
| JP2008512988A5 (enExample) | ||
| WO2005040217B1 (en) | Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions | |
| KR20050033563A (ko) | 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도 | |
| KR20060117930A (ko) | 인간 ｅｐｏ 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도 | |
| JP2011506476A (ja) | 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法 | |
| US8546321B2 (en) | IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases | |
| TW201706312A (zh) | 用以治療疾病的分子構建體 | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| WO2010109010A1 (en) | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them | |
| TW202003570A (zh) | 抗trem-1抗體及其用途 | |
| CA2975017A1 (en) | Therapeutic and diagnostic agents | |
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| US20210214434A1 (en) | Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment | |
| CN120787235A (zh) | Sars-cov-2棘蛋白特异性抗体及其用途 | |
| JP2009508476A5 (enExample) | ||
| CN113271972B (zh) | 用于替代IVIG的多聚体杂交Fc蛋白 | |
| JP7173866B2 (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| US20240076410A1 (en) | Fc-engineered anti-human ige antibodies and methods of use | |
| TW202221025A (zh) | 用於治療和預防ｃｏｖｉｄ—１９的ｓａｒｓ—ｃｏｖ—２抗體 | |
| JP2024505072A (ja) | イヌ科動物抗体の定常領域における変異 | |
| CN119136831A (zh) | 长效粒细胞巨噬细胞-集落刺激因子 | |
| JP2020060580A (ja) | 抗ｉｌ４−ｉｌ１３二重特異性抗体 |